ArticleEuropean journal of pediatrics2025
Acute kidney injury in infants with necrotising enterocolitis: A case-control study.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sepsis in neonates with necrotizing enterocolitis: outcomes and predictive model.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Necrotising enterocolitis (NEC) is a leading cause of morbidity and mortality in preterm infants. Acute kidney injury (AKI) is increasingly recognised as a common complication in this population, yet its relationship with NEC remains under-characterised. We sought to evaluate the incidence of AKI in infants with NEC and examine its association with NEC severity (using Bell staging) in a tertiary neonatal intensive care unit (NICU).
methodsA retrospective 1:2 case-control study was conducted in a single tertiary NICU between October 2018 and October 2023. Forty-nine preterm infants diagnosed with NEC were matched to 100 controls based on birth weight, gestational age, and gender. AKI was defined using modified neonatal KDIGO criteria, incorporating both serum creatinine and urine output.
resultsAKI was identified in 25 of 149 infants (16.8%), with an incidence among those with NEC of 30.6% compared to controls (10%). NEC exposure was associated with increased odds of AKI in our cohort when controlling for patent ductus arteriosus (PDA), birth weight, gentamicin and ibuprofen receipt, with an adjusted odds ratio (OR) of 3.6 (95% CI 1.3-10.2, p = 0.0129). Among NEC cases, AKI onset occurred a median of two days after diagnosis. No association was found between Bell stage and AKI incidence, albeit with a small sample size. Mortality in the NEC-AKI group was 60%, compared to 20.6% in NEC infants without AKI.
conclusionsNEC is associated with increased risk of AKI in preterm infants, when controlling for birth weight, gestational age PDA, ibuprofen and gentamicin exposure. Bell stage was not associated with AKI incidence, in our cohort. These findings support the consideration of early kidney function surveillance in NEC to inform risk stratification and improve outcomes. WHAT IS KNOWN: • NEC is a leading cause of morbidity in preterm infants, often triggering systemic inflammation and multiorgan dysfunction. AKI is common in neonates and associated with poor outcomes, but its relationship with NEC is not well defined. What is New: • In our cohort, NEC is associated with increased risk of AKI in preterm infants, when controlling for birth weight, gestational age, PDA, ibuprofen, and gentamicin exposure. NEC-associated AKI is linked to higher mortality. Consideration for routine surveillance for AKI in infants with NEC warrants further study.
Indexed as
Identifiers
41083819What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.